Navigation Links
SGX Presents Preclinical MET Data at AACR
Date:4/15/2008

licated in human cancers including JAK2 and RAS. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to the Company's MET program and the advancement of the Company's drug development and discovery pipeline. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to file INDs in the referenced time frames. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or clinical trials. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2007, as well as other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their en
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
3. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
4. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
5. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
6. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
7. Arpida Presents Preclinical Data on AR-2474 at ICAAC
8. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
9. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
10. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
11. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... -- Industry leaders from retail pharmacies ... the theme, ,Commercial Opportunities in the Era of Reform, ... Elsevier , a world-leading provider of scientific, technical ... gathering of some of the industry,s most prominent healthcare ... and in the future. The Elsevier Healthcare ...
(Date:9/30/2014)... a bio-mimicking analog of one of nature,s most ... research team led by Alejandro Briseno of the ... step in developing long-sought polymer architecture to boost ... in electronic devices. , Briseno, with colleagues ... at Stanford University and Dresden University of Technology, ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... to kill nematodes. Nematodes are microscopic parasitic roundworms, ... water, and inside other plants and animals. Nematicides ... volatility or other properties promoting migration through the ... more than 1,000 plant-parasitic nematodes. With more than ...
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. ... that it has received a Canadian Patent for ... Peptides.  This patent includes claims using thymosin beta ... actin-sequestering peptides for these purposes.  The patent will ... Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... Jan. 31, 2012  Argos Therapeutics Inc., today announced ... analysis of AGS-003-006, a Phase 2 study of ... in patients with advanced renal cell carcinoma (RCC). ... anti-tumor memory T cell responses and overall survival. ...
... 2012   Veracyte, Inc ., a molecular diagnostics company ... the appointment of Mark Spring as chief financial officer. ... has joined the Veracyte team," said Bonnie Anderson, Veracyte,s ... a CFO and senior finance leader in both public ...
... Life Technologies Corporation (NASDAQ: LIFE ) ... the following upcoming investment conferences in February. ... present at the Leerink Swann 2012 Global Healthcare Conference ... Life Technologies will also present at the 2012 ...
Cached Biology Technology:Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 2Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 3Veracyte Appoints Mark Spring as Chief Financial Officer 2Veracyte Appoints Mark Spring as Chief Financial Officer 3Life Technologies to Present at Upcoming Investment Conferences in February 2
(Date:9/30/2014)... Fish can live in almost any aquatic environment on ... up many species are pushed to the limit. The ... could prove critical for how different species cope in ... the University of Gothenburg, published in the scientific journal ... Climate change continues apace thanks to increasing levels of ...
(Date:9/30/2014)... N.C. -- Pollution in urban and farm runoff in ... new study finds. , The study, published Tuesday ... that nitrogen in the runoff ends up in algae ... on the animals, eyes, flippers and internal organs. , ... the National Oceanic and Atmospheric Administration (NOAA) conducted the ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2
... has been a well-kept secret of our immune system,s success. The ... Cell Press publication, offer an explanation for how specialized immune cells ... in the process. The focus of the study is a ... a pore in cells targeted for destruction. With that pore in ...
... uncovered a new role for a key cancer protein, a ... of a variety of tumors. Many cancers are driven ... the cells to escape growth controls and proliferate abnormally. In ... Nature , researchers discovered that cyclin D1 also helps ...
... Evidence from benchmark sites across the ... allows for land-use sharing in agriculture, forests and other ... gas emissions and raising food production levels. It provides ... land for forests through agricultural intensification. Agricultural intensification, also ...
Cached Biology News:How killer immune cells avoid killing themselves 2Cancer protein discovery may aid radiation therapy 2Cancer protein discovery may aid radiation therapy 3Integrating agriculture and forestry in the landscape is key to REDD 2
... between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) ... the lumenal surface of endothelial cells at ... primary role of PSGL-1 in mediating the ... well documented.MAB4092 completely blocks recognition of PSGL-1 ...
Mitotic Kinesin-Like Protein 1 (MKLP-1, KNSL5)...
MMP-1/8 (H-300)...
... contains choice of Printing Surface (3 glass slides coated ... layer, 1 silicon wafer coated with 1000 Angstroms of ... slides) and PDMS Stamps (3 PDMS micropatterned stamps with ... um x 10 mm or 200 um x 10 ...
Biology Products: